echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Why is China's bio 4 + 7 products still working tirelessly, with half a year's revenue down 420 million yuan?

    Why is China's bio 4 + 7 products still working tirelessly, with half a year's revenue down 420 million yuan?

    • Last Update: 2019-08-29
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Recently, China biopharmaceutical announced its annual report revenue in the first half of 2019 The total revenue in the first half of 2019 was about 12527.31 million yuan, an increase of about 28.8% compared with the same period last year The profit attributable to the holders of the parent company accounted for about 144 yuan, 4.35 million yuan, an increase of about 5.8% over the same period last year; sales of new products accounted for about 18.8% of the group's total revenue; the cash and bank balance as of June 30, 2019 was about 7181.55 million yuan The main advantages of biopharmaceuticals in China are tumor, liver disease, respiratory system medicine, analgesia, cardio cerebrovascular disease, orthopedic diseases, etc., which are also mostly involved in other fields In the first half of 2019, it can also be seen that the sales leader of China's biopharmaceuticals is still the drug for liver disease, worthy of being the "first brother" of liver disease At the same time, China biopharmaceutical has always been implementing that only by attaching great importance to R & D and innovation can it continuously improve the core competitiveness of enterprises That's why the R & D investment and product innovation ability of China biopharmaceutical are in the leading position in the industry At the same time, China biopharmaceutical also actively develops extensive cooperation with famous pharmaceutical research institutions and enterprises at home and abroad, and keeps learning new technologies To realize ecological industrialization and benefit mankind as soon as possible; Of course, it is also very important for a large enterprise to grasp the policy trend Following the pace of the times, focusing on the related expansion of the main business and overall layout of the healthy development strategy, at the same time, actively using new technologies and means such as big data, artificial intelligence and Technology Finance to continuously improve the efficiency of enterprise management, research and development, production and marketing In addition, in the 4 + 7 centralized procurement, two important products of China biopharmaceutical, Runzhong and KAIFEN, which have been on the market for many years, participated in the bidding and were selected into the list, so as to make a large profit to patients and enable more patients to use excellent products But it is also obvious that after winning the bid, the purchase volume of the two products has increased significantly However, the sales volume continued to decline, with Runzhong down by 130 million and KAIFEN down by 290 million respectively However, in the first half of 2019, China biopharmaceutical launched post marketing clinical research in a number of hospitals across the country and strengthened its professional promotion in the field of tumor by virtue of the opportunity to launch the heavyweight class 1 original new drug "focovi" Focovi's significant clinical advantages gained more doctors and patients' understanding In the first half of 2019, the sales volume continued to grow strongly, and at the same time, it also led Yigu and enishu Other tumor related products, such as Shoufu, saiweijian, etc., are growing rapidly In addition, the newly launched products for adult multiple myeloma, such as Anxin (lenalidomide capsule) and Qianping (bortezomib for injection), which are used for the treatment of relapsed or refractory mantle cell lymphoma, have also shown excellent sales performance and rapid growth after being put on the market Of course, there are also old cardiovascular drugs, such as Tuotuo and elanpine, digestive products, and respiratory products, such as Tianqing Shule, which are also growing steadily In terms of R & D investment, in order to maintain the foundation of such high-speed innovative drug research and development, China's biopharmaceuticals increased R & D investment in the first half of 2019 As of June 30, R & D expenditure was about 1.63 billion yuan, accounting for about 13.0% of the group's revenue Because of this, in the first half of 2019, China's innovative drug R & D business and R & D revenue of biopharmaceuticals also ushered in a new round of harvest period: ① In the first half of 2019, 11 new production approvals were obtained: (lenalidomide capsule, 2 specifications of linezolid and glucose injection, 2 specifications of alisentan tablets, gefitinib tablets, apixaban tablets, disodium gadolinate injection, 2 specifications of carpofungin acetate for injection, tegrilol tablets and tadalafil tablets) ② Five varieties passed the consistency evaluation, including olmesartan ester tablets, fordostan tablets, aniracetam tablets, gefitinib tablets and apixaban tablets; 8 clinical application and production were completed; ③ 9 new clinical approvals were obtained, including 4 new drugs of class 1; ④ 6 new clinical applications of class 1 new drugs in the first half of the biopharmaceutical year ⑤ 14 applications for conformity assessment were accepted ⑥ 33 new invention patents were authorized and 173 invention patent applications were filed Finally, in general, China's biopharmaceutical strategy in the first half of the year is in the direction of "innovative drugs" The generic market is no longer the main battlefield, which is basically in line with the direction of national health reform China's biopharmaceutical industry has a keen insight into the government's motivation and closely follows the government's pace Now, it seems to be very successful, compared with the first half of the year at 4 + 7 The sales volume of the two varieties under the volume purchase has declined, and the growing benefits of the new drug market may be more important The era of generic drugs is gradually disappearing, and the future will be the era of innovative drugs and original research drugs Holding the profits of generic drugs, it will only die worse, which is what smart people can foresee In addition, as for the government, it is expected that the key tasks of medical reform in the next six months will still focus on "hierarchical diagnosis and treatment" and "improving the accessibility and affordability of medical and pharmaceutical services" For the purpose of drug price reduction and reasonable use of medical insurance expenses, the "national centralized procurement with volume", "payment by disease diagnosis related groups" and "control the proportion of hospital drugs" will continue in the second half of the year, and pharmaceutical enterprises lacking core competitiveness may also face greater pressure At the same time, as the country encourages innovation and speeds up the evaluation of clinically urgent varieties such as anti-cancer drugs and drugs for rare diseases, the priority entry of children's drugs and other varieties in the new national medical insurance catalogue may give some children's drug manufacturers a chance to fight back, but perhaps more importantly, those non pediatric drug manufacturers gradually increase the penetration of pediatric drugs In fact, the situation of China's pharmaceutical industry is not as difficult as most enterprises think As long as on the one hand, it does not strengthen its R & D and innovation capabilities, and on the other hand, it cooperates with perfect technology platforms and excellent enterprises in R & D reserves to achieve mutual benefit and win-win results It can always follow the steps of the country, and stand at the end in this era of "living is winning" Statement: this opinion only represents the author, not the position of yaozhi.com, welcome to exchange and supplement in the message area; if you need to reprint, please be sure to indicate the author and source of the article.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.